Audit: QRS - Fisetin as a Senolytic Therapy
Audit conducted on 03/10/2026 17:10 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 87 |
| Failed | 0 |
| N/A | 7 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All QRS content traced to ER passages (Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions & Contraindications, Expected Benefits, Potential Risks, Monitoring Protocol, Risk Mitigation) |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “(theoretical)” and “(theoretical; protocol practice)” retained on every interaction; “Unknown in humans” and “No senolytic-dose equivalent is established” carried verbatim |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; contraindications kept as avoid items, interaction handling words (Caution, Hold, Monitor, Avoid stacking, Pause) match ER |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Modifying factors not surfaced as gates or side effects; chemotherapy/radiotherapy placed with contraindications in line with ER’s population list and “Avoid” wording |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT numbers, expert names or brand names on the sheet |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions added |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Cautious, evidence-weighted tone mirrors ER Conclusion |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms limited to ER labels and marker names; glosses kept (blood thinners, blood-pressure drugs, cell-membrane pumps) |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | At-a-glance closes with framing for health-focused adults |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Weight-based multi-day courses, monitoring cadence and functional testing presented without dilution |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | “For health-focused adults, it is a low-cost, mostly low-risk option whose central promise is still a hypothesis” |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | “orally” used in action_1_value; no lay route or event wording |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels and column headers match template |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template data-qrs-var spans present (page_title through qualitative_item_#; marker_# expanded 1-9, qualitative_item_# 1-6) |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against template shows only variable spans changed; website spans, footer and CSS untouched |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | ER High/Medium tiers carry only empty-state statements; handled by display:none per 12.5/13.5, no other empty ER section mapped |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels and interaction bold labels taken from ER; warfarin omitted from anticoagulant examples only because it is a listed contraindication (9.2) |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in file |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Each section condensed per its own rule (labels only for benefits/risks, key facts only in gates); not verified by rendering per “No Rendered Check” |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14 |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration quoted (contains colon) |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | 26.10.1 matches QRS.md |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | 2026-1003-1638 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Opus 5.5 |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Fisetin as a Senolytic Therapy - Quick Reference Sheet” |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 10/03/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “Fisetin, a plant compound sold as a dietary supplement, is being tested to clear worn-out cells…” |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses all four Conclusion paragraphs |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 68 words |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 7 ER population bullets covered (malignancy and hypersensitivity split into two items) |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Bilirubin ≥2× ULN, eGFR below 60, 5-year window preserved |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER contraindications use no ranking notation |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section not empty |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 12 ER interactions represented; chemotherapy/radiotherapy and warfarin moved to contraindications |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists and “2 days before and during” window preserved |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER interactions use no ranking notation |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section not empty |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Regimen, time of day, formulation |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides more than three actionable aspects |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | 12-week metabolic result, 1-week mouse artery measurement, “Unknown in humans” from Practical Considerations |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Low-tier benefit first, then speculative |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three aspects available |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Item names only |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high and benefits_medium set to display: none |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high and risks_medium set to display: none |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 7 table biomarkers plus home blood pressure and functional tests from the Monitoring prose |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Matches ER cadence paragraph |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 6 ER qualitative markers listed verbatim |
Issues 03/10/2026 17:10
Pass rate 100.00%. No issues found.
Issues 03/10/2026 17:06
- 1.1 — Unsupported “only” in time cell: time_2_sub (line 500) reads “Measured in old mice only”, but the ER says only “In old mice, improved artery function was measured one week after the last dose” and also reports a human conference abstract on artery widening, so “only” is not literally supported.
Fixes 03/10/2026 17:06
- 1.1 — Unsupported “only” removed: Changed time_2_sub from “Measured in old mice only” to “Measured in old mice”, matching the ER wording.
Issues 03/10/2026 17:02
- 11.4 — Non-descriptive time-to-effect label: time_3_label (QRS line 505) reads “Time to effect”, duplicating the protocol subhead instead of naming the regimen or outcome its value “Unknown in humans” refers to.
Fixes 03/10/2026 17:02
- 11.4 — Non-descriptive time-to-effect label: Changed time_3_label from “Time to effect” to “Intermittent senolytic courses” (ER Therapeutic Protocol wording), so the cell names the regimen whose human time to effect is unknown.
Issues 03/10/2026 16:57
- 1.2 / 1.3 — Radiotherapy theoretical qualifier dropped: The Contraindications item at QRS line 546 lists “radiotherapy outside oncology protocols” as an unqualified contraindication, while the ER rates radiotherapy only as “Avoid outside oncology protocols (theoretical)” (ER line 324) and does not list it among populations who should avoid fisetin.
Fixes 03/10/2026 16:57
- 1.2 / 1.3 — Radiotherapy theoretical qualifier restored: Changed the Contraindications item from “or radiotherapy outside oncology protocols” to “or radiotherapy (theoretical) outside oncology protocols”, matching the ER’s “(theoretical)” rating for radiotherapy.
Issues 03/10/2026 16:52
- 4.2 / 4.3 — Interaction labels not verbatim: Three Key Interactions labels (QRS lines 558, 559, 563) drop the ER’s plain-language glosses: “Transplant and transporter-sensitive drugs (cyclosporine, …)”, “Statins and digoxin (…)” and “NSAIDs (ibuprofen, …)” instead of the ER bold labels at ER lines 319, 320 and 328.
Fixes 03/10/2026 16:52
- 4.2 / 4.3 — Restored verbatim interaction labels: Restored the ER bold labels for three Key Interactions items: “Transplant and transporter-sensitive drugs (drugs moved by cell-membrane pumps; cyclosporine, tacrolimus, bosentan)”, “Statins (cholesterol-lowering drugs) and digoxin (…)” and “NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen, aspirin)”.
Issues 03/10/2026 16:49
- 4.5 — Sheet exceeds one A4 page: The gate lists (8 contraindications, 11 key interactions in half-width columns, several wrapping 3–4 lines, e.g., lines 546, 558–559), 9 monitoring rows and long protocol subs (line 472) are not condensed to the one-page budget.
Fixes 03/10/2026 16:49
- 4.5 — Condensed gate and protocol text: Trimmed parenthetical glosses to save space: removed drug-class names from the chemotherapy contraindication (kept the example drugs), removed “drugs moved by cell-membrane pumps”, “cholesterol-lowering drugs” and the NSAID expansion from the key interactions, and shortened action_3_sub to “No senolytic-dose equivalent is established”.
Issues 03/10/2026 16:44
- 8.4 — Chemotherapy item not concise: The stop item at QRS line 546 carries the ER gloss “classes of cancer chemotherapy” inside the parenthetical as if it were a fourth list entry, an elaboration rather than the key fact.
Fixes 03/10/2026 16:44
- 8.4 — Chemotherapy item tightened: Removed the gloss “classes of cancer chemotherapy” from the parenthetical and relabeled the item “Cancer chemotherapy (alkylating agents, anthracyclines, platinum drugs; e.g., …)”, keeping the example drugs and the “outside oncology protocols” qualifier.
Issues 03/10/2026 16:41
- 2.7 — ER plain-language glosses dropped: Key Interactions labels at QRS lines 558 and 563 drop the ER glosses “drugs moved by cell-membrane pumps” (ER line 319) and “non-steroidal anti-inflammatory drugs” (ER line 328), and the chemotherapy contraindication at QRS line 546 leaves “alkylating agents, anthracyclines, platinum drugs” unexplained despite the ER gloss “classes of cancer chemotherapy” (ER line 346).
Fixes 03/10/2026 16:41
- 2.7 — Restored ER plain-language glosses: Added “drugs moved by cell-membrane pumps” to the transporter-sensitive drugs label, “non-steroidal anti-inflammatory drugs” to the NSAIDs label, and “classes of cancer chemotherapy” to the chemotherapy contraindication, each verbatim from the ER.